Y-mAbs Therapeutics, Inc. News Releases http://ir.ymabs.com/ Y-mAbs Therapeutics, Inc. News Releases en Y-mAbs Announces Data to be Presented at 2019 ASCO Annual Meeting http://ir.ymabs.com/news-releases/news-release-details/y-mabs-announces-data-be-presented-2019-asco-annual-meeting NEW YORK , May 15, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. , (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, is pleased Wed, 15 May 2019 17:00:00 -0400 Y-mAbs Therapeutics, Inc. News Releases 6731 Y-mAbs Announces Development Update on Cancer Vaccine Program http://ir.ymabs.com/news-releases/news-release-details/y-mabs-announces-development-update-cancer-vaccine-program NEW YORK , May 14, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, is pleased to Tue, 14 May 2019 09:30:00 -0400 Y-mAbs Therapeutics, Inc. News Releases 6716 Y-mAbs Announces First Quarter 2019 Financial Results and Recent Corporate Developments http://ir.ymabs.com/news-releases/news-release-details/y-mabs-announces-first-quarter-2019-financial-results-and-recent NEW YORK , May 10, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported Fri, 10 May 2019 16:01:00 -0400 Y-mAbs Therapeutics, Inc. News Releases 6691 Y-mAbs Therapeutics To Present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas http://ir.ymabs.com/news-releases/news-release-details/y-mabs-therapeutics-present-bank-america-merrill-lynch NEW YORK , May 08, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced Wed, 08 May 2019 08:45:00 -0400 Y-mAbs Therapeutics, Inc. News Releases 6681 Y-mAbs Therapeutics To Present At The H.C. Wainwright Global Life Sciences Conference in London http://ir.ymabs.com/news-releases/news-release-details/y-mabs-therapeutics-present-hc-wainwright-global-life-sciences NEW YORK , April 03, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced Wed, 03 Apr 2019 09:00:00 -0400 Y-mAbs Therapeutics, Inc. News Releases 6651 Y-mAbs Announces 2018 Financial Results and Corporate Development Highlights http://ir.ymabs.com/news-releases/news-release-details/y-mabs-announces-2018-financial-results-and-corporate NEW YORK , March 22, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today Fri, 22 Mar 2019 16:15:00 -0400 Y-mAbs Therapeutics, Inc. News Releases 6641 Y-mAbs Therapeutics To Present At Cowen’s 39th Annual Health Care Conference http://ir.ymabs.com/news-releases/news-release-details/y-mabs-therapeutics-present-cowens-39th-annual-health-care NEW YORK , March 08, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced Fri, 08 Mar 2019 09:03:00 -0500 Y-mAbs Therapeutics, Inc. News Releases 6616 Y-mAbs Therapeutics to Present at PEGS Boston http://ir.ymabs.com/news-releases/news-release-details/y-mabs-therapeutics-present-pegs-boston NEW YORK , Feb. 13, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today Wed, 13 Feb 2019 09:00:00 -0500 Y-mAbs Therapeutics, Inc. News Releases 6606 Y-mAbs Therapeutics To Present At 37th Annual J.P. Morgan Healthcare Conference http://ir.ymabs.com/news-releases/news-release-details/y-mabs-therapeutics-present-37th-annual-jp-morgan-healthcare NEW YORK , Dec. 13, 2018 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced Thu, 13 Dec 2018 15:24:00 -0500 Y-mAbs Therapeutics, Inc. News Releases 6556 Y-mAbs Announces Appointment of Gérard Ber to its Board of Directors and Planned Departure of Michael Buschle http://ir.ymabs.com/news-releases/news-release-details/y-mabs-announces-appointment-gerard-ber-its-board-directors-and NEW YORK , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today Tue, 11 Dec 2018 17:04:00 -0500 Y-mAbs Therapeutics, Inc. News Releases 6546